IMPLANON IMPLANT FOR SUBDERMAL USE ... - epgonline.org

More documents

Recommendations

Info

ORGANON EU SmPC RA 0450 EU S6 (REF 6.0) FINAL 13 IMPLANON IMPLANT FOR SUBDERMAL USE 4.5.2 Laboratory tests Data obtained with combined OCs have shown that contraceptive steroids may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, serum levels of (carrier) proteins, e.g., corticosteroid binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. The changes generally remain within the normal range. To what extent this also applies to progestagen-only contraceptives is not known. 4.6 Pregnancy and lactation Implanon is not indicated during pregnancy. If pregnancy occurs during use of Implanon, the implant should be removed. Animal studies have shown that very high doses of progestagenic substances may cause masculinisation of female fetuses. Extensive epidemiological studies have revealed neither an increased risk of birth defects in children born to women who used OCs prior to pregnancy, nor of a teratogenic effect when OCs were inadvertently used during pregnancy. Although this probably applies to all OCs, it is not clear whether this is also the case for Implanon ® . Pharmacovigilance data with various desogestrel-containing combined OCs (etonogestrel is a metabolite of desogestrel) also do not indicate an increased risk. Implanon does not influence the production or the quality (protein, lactose or fat concentrations) of breast milk. However, small amounts of etonogestrel are excreted in breast milk. Based on daily milk ingestion of 150 ml/kg, the mean daily infant etonogestrel dose calculated after one month of etonogestrel release is approximately 27 ng/kg/day. This corresponds to approximately 2.2% of the weight-adjusted maternal daily dose and to approximately 0.2% of the estimated absolute maternal daily dose. Subsequently the milk etonogestrel concentration decreases with time during the lactation period. Limited long-term data are available on 38 children, whose mothers started using Implanon during the 4th to 8th week postpartum. They were breast-fed for a mean duration of 14 months and followed-up to 36 months of age. Evaluation of growth, and physical and psychomotor development did not indicate any differences in comparison to nursing infants whose mothers used an IUD (n=33). Nevertheless, development and growth of the child should be NL0059686
ORGANON EU SmPC RA 0450 EU S6 (REF 6.0) FINAL 14 IMPLANON IMPLANT FOR SUBDERMAL USE carefully followed. Based on the available data, Implanon may be used during lactation. 4.7 Effects on ability to drive and use machines On the basis of the pharmacodynamic profile, Implanon is expected to have no or negligible influence on the ability to drive or use machines. 4.8 Undesirable effects Possibly related undesirable effects reported in the clinical trials with Implanon have been listed in the Table below. Frequency of adverse reactions Body system Very common Common Uncommon > 1/10 < 1/10, ≥ 1/100 < 1/100, ≥ 1/1000 Skin and appendages Central and peripheral nervous system acne alopecia, pruritus, pruritus genital, rash, hypertrichosis headache dizziness migraine Psychiatric disorders Gastro-intestinal system depressive moods, emotional lability, nervousness, libido changes, appetite decreased abdominal pain, nausea, flatulence anxiety, insomnia, somnolence diarrhoea, vomiting, constipation Metabolic and nutritional increase in body weight decrease in body weight Urinary system dysuria, urinary tract infection NL0059686
Page 1 and 2: ORGANON EU SmPC RA 0450 EU S6 (REF
Page 11: ORGANON EU SmPC RA 0450 EU S6 (REF

IMPLANON IMPLANT FOR SUBDERMAL USE ... - epgonline.org

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?